SGMTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Sagimet Biosciences Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$8.86+0.84 (+10.47%)
Close on Oct 19, 2026
- Market cap
- $470.59M
- P/E (TTM)
- –
- Dividend yield
- –
Fundamental chart
Pick a measure to chart its full history
-$56.89MFY2025